Prostatism vs. Prostate Cancer: Key Differences

Prostatism (BPH) vs. Prostate Cancer: Distinct Entities

Prostatism is an outdated term for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). It is not cancer.

Pathology: Non-neoplastic proliferation of stromal/epithelial cells in transition zone
Prevalence: Histologic BPH: 50% by age 60, 90% by 85; Clinical BPH: ~50% of men >50
Symptoms (LUTS):
- Storage: Frequency, urgency, nocturia, incontinence
- Voiding: Hesitancy, weak stream, intermittency, straining, incomplete emptying
- Post-micturition: Dribbling
Complications: Retention, UTI, bladder stones, hydronephrosis (rare)
Diagnosis: IPSS questionnaire, DRE (enlarged, smooth, rubbery), PVR, Uroflow, PSA (may be elevated)
Treatment: Watchful waiting → α-blockers (tamsulosin) → 5-ARI (finasteride/dutasteride) → combination → surgery (TURP, HoLEP, UroLift, Rezūm)

Pathology: Malignant transformation of peripheral zone glandular epithelium
Incidence: Most common non-skin cancer in men; 1 in 8 lifetime risk
Symptoms: Often asymptomatic early; advanced: LUTS (obstruction), hematuria, bone pain, weight loss
Diagnosis: PSA screening → MRI → targeted biopsy (Gleason grading, Grade Groups 1–5)
Treatment: Active surveillance (low risk), radical prostatectomy, radiation, ADT, focal therapy, systemic (metastatic)

Yes. BPH and prostate cancer frequently coexist. BPH does not "turn into" cancer. Screening (PSA + MRI) detects cancer within BPH glands.

Terminology update: "Prostatism" is deprecated. Use "LUTS secondary to BPH" for precision.

Feature	BPH (Prostatism)	Prostate Cancer
Zone of origin	Transition zone	Peripheral zone (70%)
DRE	Smooth, symmetric, rubbery	Hard, nodular, asymmetric, fixed
PSA	Mild-moderate elevation (correlates with volume)	Variable; >10 ng/mL or rising velocity concerning
Natural history	Progressive LUTS; not life-threatening	Can metastasize; lethal if untreated
Treatment urgency	Quality of life driven	Risk-stratified; curative intent possible